Common Contracts

Up to USD 150,000.00 CREDIT FACILITIES AGREEMENT

Facilities Agreement • February 28th, 2020 • NLS Pharmaceutics Ltd. • Pharmaceutical preparations

• Contract Type
  Facilities Agreement
• Filed
  February 28th, 2020
• Company
  NLS Pharmaceutics Ltd.
• Industry
  Pharmaceutical preparations

WHEREAS the Company shall undertake (i) the commercial development of the patents Lauflamide and its enantiomers, the method for the preparation of the same and the therapeutic uses thereof; Phacetoperane for the treatment of attention-deficit hyperactivity disorder; and the use of iron for the treatment of attention deficit hyperactivity disorder; as well as (ii) the securement of the patents for the medicaments Quinoleine, Tryptamine and Aminoquinoaxaline;

Up to USD 7,100,000 CREDIT FACILITIES AGREEMENT

Facilities Agreement • February 28th, 2020 • NLS Pharmaceutics Ltd. • Pharmaceutical preparations

• Contract Type
  Facilities Agreement
• Filed
  February 28th, 2020
• Company
  NLS Pharmaceutics Ltd.
• Industry
  Pharmaceutical preparations

WHEREAS the Company is active in the area of the development of certain patents and know-how based on the assignment of a licence agreement entered into by NeuroLifeSciences SAS, Paris, France (“NLS FRANCE”), and Assistance Publique Hôpitaux de Paris, Paris, France (“AP-HP”), dated February 12, 2015 (“Licence Agreement”), which will be assigned by NLS FRANCE to the Company with agreement dated August 31, 2015 (“Conditional Assignment Agreement”);